AMR Action Fund — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Venatorx PharmaceuticalsMar 2022
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
Malvern, US
Board seatMartin Heidecker· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.